Anti-Obesity Drugs Market Research is Expecting to Accrue Strong Growth in Forecast to 2035

[dwaynejhonson]

Anti-obesity drugs consist of various pharmaceutical treatments aimed at helping individuals manage obesity and related health issues.

The global anti-obesity drugs market size is projected to grow from $12.8 billion in 2024 to $104.9 billion in 2035, representing a CAGR of 21.1%, till 2035. The report has been segmented into Distribution by Type of Molecule (Biologics and Small Molecules), Active Compound Used (Tirzepatide, Semaglutide, Retatrutide, Survodutide, Cagrilintide and Semaglutide, Orforglipron, Liraglutide and Other Active Compounds), Mechanism of Action (GLP-1 Agonist / GIP Agonist, GLP-1 Agonist / GCGR Agonist, GLP-1 Agonist, GLP-1 Agonist / Amylin Analogue, GLP-1 / GCGR / GIP Agonist and Other Mechanisms of Action), Type of Agonist (Single-Agonist, Dual-Agonist and Tri-Agonist), Action Pathway (Centrally Acting, Peripherally Acting and Centrally Acting, and Peripherally Acting), Route of Administration (Oral and Parenteral), Geographical Regions (North America, Europe, Asia-Pacific and Latin America), Sales Forecast and Key Players.

Several developers have the necessary capabilities to develop anti-obesity drugs, across the world. During our research, we identified 225 anti-obesity / weight loss drugs developed by close to 120 drug developers, worldwide. The anti-obesity drugs market is experiencing a steady growth, owing to the increasing prevalence of obesity and heightened awareness about the adverse effects associated with obesity.

The anti-obesity drugs market is highly fragmented, featuring the presence of both established companies as well as emerging start-ups. Notable examples of companies having a strong foothold in this industry (in alphabetical order) include Boehringer Ingelheim, Eli Lily, Novo Nordisk and Pfizer Inc. Further, majority of the companies in the weight loss drugs market are presently headquartered in North America.
Interestingly, majority of the weight loss drug candidates are currently being evaluated in the clinical stages of development; of these, around 50% of the drugs are in Phase II of clinical trials. Notable examples of these drugs (in alphabetical order) include bremelanotide (developed by Palatin), eloralintide (LY3841136) (developed by Eli Lilly) and M1Pram (developed by Adocia). Further, close to 40% of the total weight loss drugs are in the discovery / preclinical stage of development.
Further, majority of the drugs in anti-obesity drugs market can be administered through oral and subcutaneous route of administration. This can be attributed to the increased patient ccompliance and enhanced absorption rate of drugs through these routes. Examples of drugs which can be administered through both oral and subcutaneous route of administration (in alphabetical order) include GZR18 (developed by Gan & Lee Pharmaceuticals) and SCO-094 (developed by SCOHIA PHARMA).

Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Agricultural biologicals Market.


Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.  

To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/anti-obesity-drugs-market.html

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
               
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.

Contact:
Roots Analysis
[phone]
[e-mail]